Announced that it has surpassed 50% patient enrollment in MAVERIC, its Phase III randomized, double-blind, placebo-controlled, multi-center international trial evaluating CardiolRxâ„¢ for the prevention of disease recurrence in patients with recurrent pericarditis. Cardiol Therapeutics Inc. shares T.CRDL are trading unchanged at $1.35.
Stocks in play: Cardiol Therapeutics Inc.
Baystreet.ca - Baystreet - Contributor Content
This article could contain syndicated content. We have not reviewed, approved, or endorsed the content and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here